GlassScriptPhysician profile
Leonardo Marquez
NPI 1689373839
$1,737.38
in general payments reported to CMS, 2019-2025
17 companies · $901 in 2025
The $901 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $221 · 2024: $616 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,737.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $393.48 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $230.95 | 2023-2025 | Airsupra, Breztri, Bevespi Aerosphere |
| Novo Nordisk INC | $177.98 | 2023-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $162.52 | 2023-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $106.03 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Phathom Pharmaceuticals, INC. | $105.17 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $87.45 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.80 | 2023-2025 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77.18 | 2024-2025 | Caplyta |
| Amneal Pharmaceuticals LLC | $69.52 | 2024-2025 | Unithroid |
| Pfizer INC. | $69.08 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $44.68 | 2025 | Rexulti |
| Impel Pharmaceuticals INC. | $36.87 | 2023 | Trudhesa |
| Axsome Therapeutics, INC. | $34.73 | 2025 | Auvelity |
| Myriad Women'S Health, INC. | $26.03 | 2023 | Myrisk |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $20.29 | 2025 | Veozah |
| Paratek Pharmaceuticals, INC. | $14.62 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonardo Marquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.